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ABSTRACT
Objective: A biomarker with increased specificity for
cervical dysplasia compared with human
papillomavirus (HPV) testing would be an attractive
option for cervical cancer screening among
HIV-infected women in resource-limited settings.
p16INK4a has been explored as a biomarker for
screening in general populations.
Design: A 2-year cross-sectional study.
Setting: 2 large HIV primary care clinics in western
Kenya.
Participants: 1054 HIV-infected women in western
Kenya undergoing cervical cancer screening as part of
routine HIV care from October 2010 to November
2012.
Interventions: Participants underwent p16INK4a
specimen collection and colposcopy. Lesions with
unsatisfactory colposcopy or suspicious for cervical
intraepithelial neoplasia 2+ (CIN2+; including CIN2/3 or
invasive cervical cancer) were biopsied. Following
biopsy, disease status was determined by
histopathological diagnosis.
Primary and secondary outcome measures:
We measured the sensitivity, specificity and predictive
values of p16INK4a ELISA for CIN2+ detection among
HIV-infected women and compared them to the test
characteristics of current screening methods used in
general as well as HIV-infected populations.
Results: Average p16INK4a concentration in cervical
samples was 37.4 U/mL. After colposcopically directed
biopsy, 127 (12%) women were determined to have
CIN2+. Receiver operating characteristic analysis
showed an area under the curve of 0.664 for p16INK4a
to detect biopsy-proven CIN2+. At a p16INK4a cut-off
level of 9 U/mL, sensitivity, specificity, positive and
negative predictive values were 89.0%, 22.9%, 13.6%
and 93.8%, respectively. The overall p16INK4a positivity
at a cut-off level of 9 U/mL was 828 (78.6%) women.
There were 325 (30.8%) cases of correct p16INK4a
prediction to detect or rule out CIN2+, and 729
(69.2%) cases of incorrect p16INK4a prediction.
Conclusions: p16INK4a ELISA did not perform well as
a screening test for CIN2+ detection among
HIV-infected women due to low specificity. Our study
contributes to the ongoing search for a more specific
alternative to HPV testing for CIN2+ detection.
INTRODUCTION
HIV-related immunosuppression signiﬁcantly
increases the incidence and persistence of
infection with oncogenic human papilloma-
virus (HPV),1 leading to higher risk for
development of cervical precancer and
cancer. Compared with HIV-negative women,
HIV-infected women have higher cervical
cancer morbidity and mortality, including
Strengths and limitations of this study
▪ This study is the first to investigate p16INK4a
ELISA as a primary cervical cancer screening
tool in an HIV-infected population.
▪ The very large sample size of 1054 HIV-infected
women provides well-powered estimates of the
sensitivity, specificity and predictive values of
p16INK4a ELISA.
▪ In order to evaluate p16INK4a as a stand-alone
biomarker for cervical cancer screening, our
study uses methods that would be feasible and
readily employable in low-resource settings,
including performing non-directed p16INK4a spe-
cimen collection instead of preferentially sam-
pling acetowhite lesions via colposcopy. This
non-directed sampling may have decreased the
sensitivity and specificity of p16INK4a for cervical
intraepithelial neoplasia 2+ (CIN2+) detection,
compared with prior studies.
▪ We ascertained disease using colposcopy with
biopsy only of lesions that appeared suspicious
for CIN2+, which may have led to underascer-
tainment of true disease, and to a lower preci-
sion of our sensitivity and specificity estimates.
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younger age of onset and more advanced malignancies
at presentation, leading to lower survival rates.2–4
Moreover, both diseases disproportionately affect women
in low-resource countries. In sub-Saharan Africa, there
are 24.7 million HIV-infected people5 and 70 000 new
cases of invasive cervical cancer (ICC) each year.6
Recent advances in HIV/AIDS care, especially improved
access to highly active antiretroviral therapy (HAART),
have decreased AIDS-related mortality.7 Studies on the
impact of HAART on risk of cervical precancer or
cancer have shown inconsistent results. In some studies,
HAART has not been shown to reduce the risk of cer-
vical precancer or cancer;8 9 in other studies, it has been
shown to increase or decrease risk of cervical disease,
depending on HAART duration or adherence.10 11
Therefore, it is possible that HIV-infected women in low-
resource settings are now living longer, but remain at
higher risk for cervical disease. Unfortunately, many of
these settings offer limited or no access to cervical
cancer screening programmes.12
Cytology-based screening programmes, though suc-
cessful in resource-replete settings, are not always the
best option in low-resource settings due to costs, labora-
tory infrastructure and need for multiple visits.13–16 The
WHO published updated guidelines for screen-and-treat
strategies for cervical cancer control in low-resource
countries in 2013.17 These guidelines preferentially rec-
ommend screening with HPV testing, followed by treat-
ment for women who test positive. However, among
HIV-infected women, high HIV-HPV co-infection rates
lead to concerns about decreased speciﬁcity for cervical
disease.18 19 With rates of HPV positivity up to 75% in
HIV-infected women,20 HPV testing could lead to an
overburdening of the referral system or overtreatment in
screen-and-treat settings. With limitations to current
screening options, a resource-appropriate objective
method for testing HIV-infected women is needed.
A biomarker with increased speciﬁcity for detection of
cervical intraepithelial neoplasia 2+ (CIN2+), including
CIN2/3 and ICC, would decrease the referral burden
and overtreatment inherent in an HPV-based screening
programme. One such candidate, p16INK4a, is a cyclin-
dependent kinase inhibitor overexpressed in
HPV-transformed cells, but rarely in normal tissue.21 As
an adjunct to traditional stains, p16INK4a immunohisto-
chemical (IHC) staining signiﬁcantly improves interob-
server agreement in histological assessment, and
adjudication of CIN1 compared with CIN2+.22 An ELISA
has been developed using simple technology to measure
p16INK4a levels from a swab of exfoliated cervical cells.23
p16INK4a ELISA showed signiﬁcantly improved speciﬁcity
for CIN2+ lesions among a screening population com-
pared with HPV testing.23 24
p16INK4a ELISA has not been widely studied in an
HIV-infected population or in low-resource settings. We
conducted a cross-sectional study in an HIV primary
care setting in western Kenya to measure the sensitivity,
speciﬁcity and predictive values of p16INK4a ELISA for
CIN2+. We sought to describe the test characteristics in
a study that was adequately powered to examine the
demographic, HIV-related and reproductive factors
impacting test accuracy.
MATERIALS AND METHODS
Study design
We conducted a cross-sectional study to deﬁne the sensi-
tivity, speciﬁcity, positive and negative predictive values
of p16INK4a ELISA among HIV-infected women undergo-
ing cervical cancer screening as part of routine HIV care
at the Family AIDS Care and Education Services
(FACES) programme in Kisumu, Kenya.25 Women
receive HIV education talks at the time of enrolment
with information about basic gynaecological care, cer-
vical cancer and strategies for screening.26 Women with
serologically conﬁrmed HIV infection, enrolled in HIV
care and eligible for cervical cancer screening, were
recruited for participation. Screening eligibility criteria
included women who were 23 years or older, not preg-
nant, had no prior history of cervical cancer, had an
intact uterus and cervix and had no lesion suspicious for
cancer on examination.
Measurements and examination
After signing informed consent, participants underwent
pelvic examination with p16INK4a specimen collection
using a collection brush swirled three times at the cer-
vical os to capture exfoliated cells from the transform-
ation zone. This was followed by visual inspection with
acetic acid (VIA). After VIA, the initial clinician left the
room and colposcopy was performed by a second
trained clinician who was blinded to VIA results.
The study staff (one nurse and one clinical ofﬁcer)
were trained and certiﬁed to perform colposcopy inde-
pendently and had each performed over 300 colposco-
pies before study initiation. Colposcopic assessment was
carried out in four steps. Clinicians identiﬁed normal
cervical anatomy before and after acetic acid, using a
green ﬁlter and after application of Lugol’s iodine.
Results were classiﬁed as normal, cervicitis, probable
CIN1 or probable CIN2+. Women with a satisfactory col-
poscopy with no lesions were determined to have no
disease.27 Women with unsatisfactory colposcopy, or
visual impression of CIN2+ underwent cervical biopsy or
endocervical curettage at the time of colposcopy.
Disease status was determined by histopathological diag-
nosis in women who underwent biopsies.
Biopsy specimens were stored in 10% buffered forma-
lin at room temperature, and sent to the Department of
Human Pathology Laboratory at the University of
Nairobi for independent interpretation by two histo-
pathologists. Specimens were read as normal, cervicitis,
CIN1, CIN2/3 or invasive cancer. For women with two
or more biopsies taken, the outcome was determined by
the most severe diagnosis. For women with discrepant
results from the same biopsy, ﬁnal diagnosis was
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determined by consultation and consensus between
both histopathologists. Treatment decisions were based
on histopathology results.
Demographic and clinical variables collected at the
time of the visit included age, relationship status,
number of partners, reproductive history, contraceptive
use and current HAART regimen. Additional clinical
variables were obtained from the paper ﬁle and elec-
tronic medical record. These included veriﬁcation of
HAART regimens, most recent CD4+ count, WHO stage,
time since HIV diagnosis, duration of enrolment into
HIV care and duration on HAART.
Laboratory methods
Specimens for p16INK4a ELISA were collected on a cyto-
brush and transferred into a specimen collection vial
with a prototypic sample lysis medium (MTM
Laboratories, Heidelberg, Germany). Samples were heat
stabilised at 100°C for 3 min within 30 min of collection
and then stored in a −80°C freezer. Specimens were
shipped on dry ice to the Department of Applied
Tumor Biology at the German Cancer Research Center
(DKFZ) in Heidelberg, Germany and/or the onsite
FACES laboratory. A total of 460 (43.6%) women had
samples sent to DKFZ, while 740 (70.2%) women had
samples sent to the onsite FACES laboratory. Among the
total cohort, 146 (13.9%) women had samples sent to
both sites. The interclass correlation coefﬁcient of
p16INK4a values at the two sites was 0.89, which con-
ﬁrmed that p16INK4a ELISA would perform independ-
ently with valid and reproducible results in the FACES
laboratory. In the laboratory, 100 μL aliquots of each pro-
cessed sample were subjected in duplicate to a proto-
typic calorimetric sandwich-ELISA protocol (Cervatec,
MTM Laboratories). Two p16INK4a-speciﬁc monoclonal
antibodies were used: a capture antibody coated to the
solid phase of a microtitre plate and a tracer antibody
conjugated to horseradish peroxidase for detection of
captured p16INK4a protein. For quantiﬁcation of solubi-
lised p16INK4a values, calibration curves had been estab-
lished according to the manufacturer’s protocol.
p16INK4a concentrations in individual samples were cal-
culated as arbitrary units (U/mL) using the standardised
curve. For specimens analysed in both laboratories, the
p16INK4a values were averaged.
Statistical methods
We based our sample size calculations on the CIN2+
prevalence of 7.2% previously seen in this clinic.26 We
calculated that a sample size of 1100 women was needed
to achieve a p16INK4a ELISA anticipated sensitivity
between 70% and 80% with 95% CI 5% to −5%, com-
parable to that of cytology screening and VIA. To attain
an anticipated speciﬁcity between 80% and 90% with
95% CI 5% to −5%, 500 women needed to be exam-
ined. Power analysis was performed using Power Analysis
and Sample Size Software (PASS): V.2008 (National
Council for Social Studies, Kaysville, Utah).
We built receiver operating characteristic (ROC)
curves to determine the p16INK4a cut-off values with the
highest combined sensitivity and speciﬁcity for CIN2+, as
determined by the area under the curve (AUC). Using
the value with the greatest AUC, sensitivity, speciﬁcity,
positive and negative predictive values of p16INK4a for
detection of CIN2+ were calculated. Sensitivity analysis
was performed for different outcomes, including CIN1+
(deﬁned as CIN1, CIN2/3 and ICC) diagnosis by
colposcopy or biopsy, CIN2+ diagnosis by only
colposcopy or CIN1+ diagnosis by only colposcopy.
Stratiﬁed analysis was performed by looking at test per-
formance calculations after stratiﬁcation by age (<35 or
≥35 years), HAART status, duration on HAART (≤18
or >18 months) or most recent CD4+ count (≤350 or
>350 cells/dL).
In order to determine the performance of p16INK4a at
the determined cut-off threshold, we created a dicho-
tomous variable named ‘p16INK4a prediction’, with two
possible outcomes: correct or incorrect. Correct was
deﬁned as accurately detected cases of CIN2+ (true posi-
tives) and non-CIN2+ (true negatives). Women were clas-
siﬁed as correct if they had p16INK4a greater than or
equal to the determined threshold with biopsy-
conﬁrmed CIN2+ (positive gold standard result), or if
they had p16INK4a less than the threshold and no CIN2+
by colposcopy or biopsy (negative gold standard result).
Women were classiﬁed as incorrect if the p16INK4a value
did not correctly predict the presence or absence of
CIN2+. Women were classiﬁed as incorrect if they had
p16INK4a greater than or equal to the threshold and no
CIN2+ by colposcopy or biopsy, or if they had p16INK4a
less than the threshold and biopsy-conﬁrmed CIN2+.
Student’s t-tests were performed for continuous vari-
ables, while χ2 tests were performed for categorical vari-
ables. Predictors found to be statistically signiﬁcantly
associated with correct p16INK4a prediction on univariate
analysis (p<0.05) were included in the multivariate logis-
tic regression model. Fit of the regression model was
tested using R2. Statistical analysis was performed using
Stata V.13 (StataCorp, College Station, Texas, USA).
RESULTS
Between 25 October 2010 and 30 November 2012, 1134
HIV-infected women undergoing cervical cancer screen-
ing at FACES were enrolled in the study and underwent
p16INK4a specimen collection and colposcopy with
biopsy as indicated. Of these, 1054 (92.9%) had com-
plete p16INK4a values and colposcopy and biopsy results
(ﬁgure 1). The average age of participants was
34.5 years (±SD 7.8), 824 (78.2%) were on HAART,
average duration on HAART was 18.0 months and
median most recent CD4+ count was 506 cells/dL (IQR
355–685; table 1).
At colposcopy, 203 (19.3%) women were biopsied on
suspicion of CIN2+; of these, 126 (62.1%) had CIN2/3
conﬁrmed on biopsy and 1 (0.5%) had stage IA1 ICC
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(ﬁgure 1). Colposcopy and biopsy results were com-
bined to determine the ﬁnal number of women with
normal results, cervicitis or CIN1. For example, women
were considered to have CIN1 if they had CIN1 on col-
poscopy alone (no biopsy), if they had unsatisfactory col-
poscopy and CIN1 conﬁrmed on biopsy or if they had
the impression of CIN2+ on colposcopy and CIN1 con-
ﬁrmed on biopsy. Among the 1054 participants, a total
of 747 (70.9%) women had normal results, 160 (15.2%)
women had CIN1, 126 (11.9%) women had CIN2/3, 20
(1.9%) women had cervicitis and 1 (0.1%) woman had
stage IA1 ICC.
The mean concentration of p16INK4a protein in cer-
vical samples was 37.4 U/mL (±SD 42.0). The mean
p16INK4a in the 747 women with normal results on col-
poscopic impression or biopsy was 32.6 U/mL (±SD
36.2). Mean p16INK4a in the 160 women with CIN1 on
colposcopic impression or biopsy was 38.7 U/mL (±SD
41.5). Mean p16INK4a in the 126 women with biopsy-
conﬁrmed that CIN2/3 was 63.4 U/mL (±SD 59.7). The
p16INK4a value in the woman with stage IA1 ICC was
210.0 U/mL. In these stratiﬁed results, women with
cervicitis (mean p16INK4a=34.4 U/mL±SD 42.5) were
excluded in the calculation of mean p16INK4a values, as
they did not constitute normal results nor any form of
premalignant disease.
ROC analysis showed an AUC of 0.6639 for p16INK4a
to detect biopsy-proven CIN2+ (ﬁgure 2A). The sensiti-
vity analyses changing the outcome to any biopsy-proven
or visual impression of CIN1+ (ﬁgure 2B) decreased the
AUC to 0.6078. The AUC was 0.6445 for colposcopic
impression only (without biopsy conﬁrmation) of CIN2+
(ﬁgure 2C) and 0.6133 for colposcopic impression only
of CIN1+ (ﬁgure 2D).
The p16INK4a cut-off value with the highest combined
sensitivity (89.0%) and speciﬁcity (22.9%) for biopsy-
proven CIN2+ was 9 U/mL (table 2). The positive pre-
dictive value was 13.6% and negative predictive value was
93.8%. Overall, the p16INK4a positivity with the selected
9 U/mL cut-off level was 828 (78.6%) women; in com-
parison, biopsy-proven CIN2+ was found in only 127
(12%) women. When stratiﬁed by age (<35 or
≥35 years), HAART status, average duration on HAART
(≤18 or >18 months) or most recent CD4+ count (≤350
or >350 cells/dL), no signiﬁcant differences were found
in regard to sensitivity, speciﬁcity or predictive values
(table 2).
Using a threshold p16INK4a level of 9 U/mL to predict
CIN2+ diagnosis, there were 325 (30.8%) cases of
correct p16INK4a prediction and 729 (69.2%) cases of
incorrect p16INK4a prediction. On univariate analysis,
age, relationship status, number of current partners,
prior pregnancies, deliveries and delivery type, whether
women were experiencing vaginal symptoms, amenor-
rhoea, menopause and time since HIV diagnosis were
associated with correct p16INK4a prediction (p<0.05;
table 3), and therefore were included in the ﬁnal logistic
regression model. An R2 value (range from 0 to 1) to
measure the goodness-of-ﬁt of our model to the data was cal-
culated to be 0.0553 (p=0.001), indicating that our model
gave little predictive information about the outcome of
correct versus incorrect p16INK4a prediction.
DISCUSSION
p16INK4a ELISA showed potential to be an effective cer-
vical cancer screening test in low-resource settings based
on its molecular function and performance on IHC and
in prior studies in general populations. However, in our
cohort of 1054 HIV-infected women, the assay did not
Figure 1 Flow sheet of study enrolment, eligibility and
outcomes. CCID, Cross-Sectional Study ID; CIN2+, cervical
intraepithelial neoplasia 2+.
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perform well as a screening test. Our study provides well-
powered estimates of the sensitivity and speciﬁcity of
p16INK4a ELISA among HIV-infected women. We
observed a similar sensitivity but much lower speciﬁcity
compared with current screening methods used in the
general population (high-risk HPV (HR-HPV) testing,
Pap smear and VIA).28 Speciﬁcities are ∼73.9% for
HR-HPV testing, 94.6% for Pap smear and 80.0% for
Table 1 Baseline characteristics of women screened with p16INK4a ELISA (n=1054)
Characteristic n* Mean/median or n SD (IQR) or per cent†
Age (mean, years) 1054 34.5 7.8
Relationship status 1043
Single 76 7.3%
Married 565 54.1%
Separated 105 10.1%
Widowed 297 28.5%
Number of current partners 1053
0 269 25.6%
1 771 73.2%
>1 13 1.2%
Number of previous partners (median) 1047 3 (2–4)
Number of lifetime partners (median) 1053 4 (3–5)
Age of first intercourse (mean, years) 1048 17.3 2.7
Reproductive history
Gravidity (median) 1054 3 (2–4)
Parity (median) 1053 3 (1–4)
Currently experiencing vaginal symptoms‡ 1050 397 37.8%
Amenorrhoea 1050 165 15.7%
Postmenopausal§ 1050 98 9.3%
Had vaginal delivery 1042 953 91.5%
Had caesarean section 1052 129 12.3%
History of STI 1046 116 11.1%
Current contraceptive use
Any contraception 1054 402 38.1%
Hormonal contraception 1054 314 29.8%
Duration of contraceptive use (mean, moths) 380 33.1 38.0
Contraception by type 402
Oral contraceptives 31 7.7%
Injectable (Depo Provera) 200 49.8%
Implant ( Jadelle or Norplant) 83 20.6%
Intrauterine device in situ (copper) 10 2.5%
Female sterilisation 63 15.7%
Condom only 15 3.7%
HIV-related characteristics
Time since first HIV diagnosis (mean, months) 1054 45.1 29.7
WHO stage 1053
1 292 27.7%
2 310 29.5%
3 377 35.8%
4 74 7.0%
Most recent CD4+ count (median, cells/dL) 1054 506 (355–685)
<200 91 8.6%
200–349 165 15.7%
350–499 255 24.2%
≥500 543 51.5%
On HAART 1054 824 78.2%
Time from HIV diagnosis to HAART
initiation (mean, months)
805 26.0 26.3
Duration on current HAART (mean, months) 1054 18.0 21.0
*N was different due to missing demographic information.
†Mean with SD was used to describe normally distributed variables. Median with IQR was used to describe non-normally distributed
variables.
‡Vaginal symptoms included abnormal discharge, itching or pain with intercourse.
§Postmenopausal was not a subset of amenorrhoea.
HAART, highly active antiretroviral therapy; STI, sexually transmitted infection.
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VIA among the general population. Compared with sen-
sitivity and speciﬁcity values from studies of HR-HPV
testing in HIV-infected women, p16INK4a ELISA per-
formed with similar sensitivity but lower speciﬁcity.29 30
Speciﬁcities from these studies were 55.7% and 77.4%,
respectively.
Differences between our study and other p16INK4a
ELISA studies can be attributed to characteristics of the
study setting and population. Our setting was an HIV
care clinic in East Africa, compared with a general clinic
population in developed countries. In order to evaluate
the performance of p16INK4a as a stand-alone biomarker
for cervical cancer screening, we collected the specimen
prior to VIA or colposcopy. Prior studies have preferen-
tially sampled acetowhite lesions, which may have
increased the accuracy of p16INK4a. In addition,
HIV-infected women may have intrinsic differences in
p16INK4a expression, reﬂected in the higher mean
p16INK4a concentration seen among our population.
Overall, our mean p16INK4a concentration was 37.4 U/mL,
compared with 33 U/mL in a previous study among the
general population. Speciﬁcally, we had much higher
p16INK4a concentrations within the subset of women
with non-CIN2+. Our mean p16INK4a concentration
among women with normal cervical examinations
(32.6 U/mL) was four times higher than that among
women with normal cervical examinations in the other
study (8.7 U/mL).23 Our higher p16INK4a levels among
HIV-positive women may reﬂect higher rates of infection
with HR-HPV subtypes in HIV-infected women com-
pared with HIV-negative women. There is higher
p16INK4a in infections by HR-HPV subtypes, compared
with low-risk subtypes.31 32 It is also possible that higher
p16INK4a levels reﬂect higher HPV viral loads among
HIV-positive women, even when comparing HIV-positive
and HIV-negative women infected by the same HPV
subtype. A recent study showed that among HIV-positive
and HIV-negative women with normal Pap tests but who
tested positive for a HR-HPV subtype (HPV 16),
HIV-positive women were still found to have a 1.4–2.2
times higher risk for developing CIN2+ in 5 years;33 this
may be attributed to HIV-positive women having higher
Figure 2 ROC curves (sensitivity vs 1—specificity) in primary and sensitivity analyses (n=1054). (A) Base case: true positives
limited to biopsy-proven CIN2+. CIN2+ includes CIN2/3 and ICC. All other diagnoses were considered negative. AUC=0.6639.
(B) Sensitivity analysis (1): true positives included any biopsy-proven or visual impression of CIN1+. CIN1+ includes CIN1, CIN2/
3 and ICC. AUC=0.6078. (C) Sensitivity analysis (2): true positives included any visual impression of CIN2+ by colposcopy.
AUC=0.6445. (D) Sensitivity analysis (3): true positives included any visual impression of CIN1+ by colposcopy. AUC=0.6133.
AUC, area under the curve; CIN2+, cervical intraepithelial neoplasia 2+; ICC, invasive cervical cancer; ROC, receiver operating
characteristic.
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Table 2 Test characteristics of p16INK4a ELISA for biopsy-proven CIN2+* in primary and stratified analyses (n=1054)
Primary analyses: sensitivity and specificity of p16INK4a ELISA at varying cut-off levels
p16INK4a ELISA cut-off levels (U/mL) Sensitivity (%) Specificity (%)
7 90.6 18.2
8 89.8 20.6
9 89.0 22.9
10 85.8 26.9
Primary analyses: sensitivity, specificity, positive and negative predictive values of p16INK4a ELISA at the optimal cut-off level
p16INK4a ELISA test performance (%) p16INK4a cut-off level=9 U/mL (%)
Sensitivity 89.0
Specificity 22.9
Positive predictive value 13.6
Negative predictive value 93.8
Overall p16INK4a positivity 78.6
Prevalence of CIN2+ 12.0
Stratified analyses: test characteristics of p16INK4a ELISA stratified by age-related and HIV-related characteristics
p16INK4a ELISA test performance (%) Age (years) (%) HAART status (%)
Average duration on
HAART (months) (%)
Most recent CD4+
count (cells/dL) (%)
≥35 <35 Yes No >18 ≤18 >350 ≤350
Sensitivity 86.1 90.5 90.6 83.9 86.11 90.11 87.5 91.5
Specificity 20.5 24.9 22.0 26.1 22.37 23.74 23.8 19.6
Positive predictive value 9.9 16.7 13.3 15.0 9.72 16.1 11.3 20.4
Negative predictive value 93.5 94.0 94.7 91.2 94.3 93.5 94.5 91.1
*CIN2+ includes CIN2/3 and ICC.
CIN2+, cervical intraepithelial neoplasia 2+; ICC, invasive cervical cancer.
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Table 3 Univariate analyses of factors associated with correct p16INK4a prediction of CIN2+
Correct p16INK4a prediction*
Incorrect p16INK4a
prediction†
Variable Mean or n SD or per cent Mean or n SD or per cent p Value
Age 33.04 0.76 35.1 0.58 0.0001
Relationship status
Single 36 11% 40 6% 0.01
Married 176 54% 389 54%
Separated 30 9% 75 10%
Widowed 81 25% 216 30%
Number of current partners 0.81 0.04 0.73 0.03 0.01
Number of previous partners 3.7 0.26 3.99 0.39 0.36
Number of lifetime partners 4.62 0.3 4.74 0.4 0.73
Age at first intercourse 17.41 0.31 17.21 0.18 0.26
Reproductive history
Gravidity 2.87 0.22 3.65 0.16 0.0001
Parity 2.38 0.2 3.15 0.15 0.0001
Currently experiencing vaginal symptoms
No 178 55% 475 65% 0.00
Yes 145 45% 252 35%
Amenorrhoea
No 284 88% 601 83% 0.03
Yes 39 12% 126 17%
Menopause
No 305 94% 647 89% 0.01
Yes 18 6% 80 11%
Number of vaginal deliveries 2.52 0.21 3.4 0.15 0.0001
Number of caesarean sections 0.3 0.07 0.14 0.03 0.0001
History of STI
No 282 88% 648 90% 0.36
Yes 40 12% 76 10%
Current contraceptive use
Any contraception
No 208 64% 444 61% 0.34
Yes 117 36% 285 39%
Hormonal contraception
No 237 73% 503 69% 0.20
Yes 88 27% 226 31%
Duration of contraception use (months) 29.05 6.65 34.64 4.66 0.20
Contraception by type
Oral contraceptives 9 8% 22 8% 0.32
Injectable (Depo Provera) 60 51% 140 49%
Implant ( Jadelle or Norplant) 19 16% 64 23%
Intrauterine device in situ (copper) 3 3% 7 2%
Female sterilisation 18 15% 45 16%
Condom only 8 7% 7 2%
HIV-related characteristics
Time since first HIV diagnosis (months) 42.21 3.15 46.36 2.18 0.04
Most advanced WHO stage
1 100 31% 192 26% 0.51
2 91 28% 219 30%
3 111 34% 266 37%
4 22 7% 52 7%
Most recent CD4+ count (cells/dL) 518 28 543 20 0.16
Most recent CD4+ count by category (cells/dL)
<200 33 10% 58 8% 0.61
201–350 51 16% 114 16%
351–500 73 22% 182 25%
>500 168 52% 375 51%
Continued
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HPV viral loads. The higher overall p16INK4a concentra-
tion in HIV-positive women indicates that it is critical to
set an optimal p16INK4a threshold.
Differentiation between CIN2+ and non-CIN2+ had
the greatest AUC compared with differentiation between
CIN1+ and non-CIN1+ (ﬁgure 2A, B). We did not differ-
entiate between different types of high-grade CIN (CIN2
vs CIN3) in data collection, because management more
signiﬁcantly differs between women with CIN1 and
CIN2+; treatment guidelines in a screen-and-treat strat-
egy are similar for women diagnosed with CIN2 and
CIN3. In our study, there is a dose-dependent increase
in mean p16INK4a values from HIV-positive women with
normal results (32.6 U/mL) to those with progressive
levels of cervical dysplasia and cancer (38.7 U/mL for
CIN1 to 63.4 U/mL for CIN2/3 to 210 U/mL for ICC).
This suggests that p16INK4a is a promising biomarker in
measuring progression of cervical disease. However, it
may be difﬁcult to choose a numerical threshold to dis-
tinguish CIN1 from CIN2+ in a population of women
with high rates of HPV positivity and low-grade dysplasia.
Limitations include intrinsic study characteristics such
as the global p16INK4a specimen collection, rather than
directed collection from acetowhite areas, which could
have improved our test performance. The collection
protocol was adopted to simulate performance by provi-
ders without training in VIA, as would be the case in
low-resource settings. Although we performed biopsy
only for positive colposcopic ﬁndings as is the common
validation method in similar studies,29 30 this may have
led to underascertainment of true CIN2+ cases, which
meant that our test characteristics may have underesti-
mated true sensitivity and overestimated true speciﬁcity
of the p16INK4a ELISA. While p16INK4a IHC staining as
an adjunct to H&E staining signiﬁcantly improves
interobserver agreement and adjudication of CIN1 vs
CIN2+,22 we limited our cohort assessment to H&E stain-
ing to maintain a dichotomous result for calculations.
Although these additional procedures would have
increased the accuracy of our test estimates, we decided
not to perform them due to the unacceptability of
added invasive procedures and widespread use of H&E
alone for disease ascertainment and management.
Given these limitations, additional studies investigating
the utility of p16INK4a as a biomarker or other novel
methods are warranted to improve ﬁrst-line screening
options for the vulnerable population of HIV-infected
women. p16INK4a cytology methods such as CINtec Plus,
an immunocytochemistry assay detecting p16INK4a and
Ki-67 proteins, may be appropriate. This dual-stained
cytology method showed higher speciﬁcity and a positive
predictive value for CIN2+ than HPV testing among a
general population in European countries with abnor-
mal cytology results (including atypical squamous cells
of undetermined signiﬁcance or low-grade squamous
intraepithelial lesions),34 and also recently showed
promising results among a resource-limited screening
population in Kenya.35
On the basis of our ﬁndings, p16INK4a ELISA mea-
sured in exfoliated cervical cells did not perform well as
a cervical cancer screening test among HIV-infected
women. We found a low speciﬁcity and positive predict-
ive value for CIN2+. The low speciﬁcity of p16INK4a
ELISA could result in an overburdening of the referral
system and overtreatment in screen-and-treat settings.
With the additional considerations for cervical cancer
screening among HIV-infected women in low-resource
settings, our study contributes to the ongoing search for
a feasible alternative with high sensitivity and speciﬁcity
for CIN2+.
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Table 3 Continued
Correct p16INK4a prediction*
Incorrect p16INK4a
prediction†
Variable Mean or n SD or per cent Mean or n SD or per cent p Value
HAART status
Not on HAART 78 24% 152 21% 0.25
On HAART 247 76% 577 79%
Time from HIV diagnosis to
HAART initiation (months)
23.86 3.22 26.96 2.2 0.12
Duration on current HAART (months) 16.48 2.17 18.66 1.56 0.12
*Correct p16INK4a prediction included women whose p16INK4a value accurately predicted the presence or absence of CIN2+, which included
CIN2/3 and ICC. Women were classified as correct if they had p16INK4a≥9 U/mL and CIN2+, or if they had p16INK4a<9 U/mL and non-CIN2+.
†Incorrect p16INK4a prediction included women whose p16INK4a value did not accurately predict the presence or absence of CIN2+. Women
were classified as incorrect if they had p16INK4a≥9 U/mL and non-CIN2+, or if they had p16INK4a<9 U/m and CIN2+.
CIN2+, cervical intraepithelial neoplasia 2+; HAART, highly active antiretroviral therapy; ICC, invasive cervical cancer; STI, sexually
transmitted infection.
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